2026 Medicare Part D: Capping Costs on Retail Prescription Drugs

Part D Retail Prescription Drugs – Image for illustrative purposes only (Image credits: Flickr)

Millions of Americans enrolled in Medicare turned to Part D plans last year for help affording everyday medications purchased at retail pharmacies. These voluntary programs, run by private insurers, cover a broad array of outpatient prescription drugs that Original Medicare does not include.[1][2] In 2026, the program features a redesigned structure that eliminates previous coverage gaps and limits annual out-of-pocket spending at $2,100 for covered drugs.[3]

What Counts as Retail Prescription Coverage Under Part D

Part D targets medications beneficiaries pick up from retail, mail-order, or long-term care pharmacies, distinguishing it from hospital-administered drugs covered elsewhere in Medicare. Plans maintain formularies – lists of approved drugs – that dictate coverage and cost-sharing tiers, from low-cost generics to pricier brands. Most plans organize drugs into tiers, with lower tiers carrying smaller copays or coinsurance.

Federal rules require coverage of certain protected classes to ensure access to critical treatments. These include medications for cancer, HIV/AIDS, depression, psychosis, seizures, and organ transplant rejection.[1] Many recommended vaccines, such as those for shingles or RSV, also qualify if listed on the formulary. Beneficiaries can request exceptions for non-covered drugs, and plans must cover a wide range to meet Medicare standards.

• Cancer treatments (antineoplastic drugs)
• HIV/AIDS antiretrovirals
• Antidepressants
• Antipsychotics
• Anticonvulsants for seizures
• Immunosuppressants for transplants

The 2026 Benefit Phases Explained

Costs under Part D progress through simplified phases in 2026, a shift from prior years that closed the notorious “donut hole.” Coverage begins after any deductible, then applies uniform coinsurance until the spending threshold triggers full plan payment. This structure applies specifically to retail prescriptions, including insulin at a capped $35 monthly cost for one-month supplies.

Plans vary in details, but all adhere to federal maximums. The redesign streamlines protection against high expenses, particularly for those with multiple or costly medications.

Premiums, Penalties, and Out-of-Pocket Limits

Average monthly premiums for stand-alone Part D plans hovered around $36 to $46 last year, depending on location and options selected. Higher earners face income-related monthly adjustment amounts, or IRMAA, starting at modified adjusted gross incomes over $109,000 for individuals. Delaying enrollment without equivalent creditable coverage triggers a permanent penalty: 1% of the $38.99 national base beneficiary premium per uncovered month.

The $2,100 out-of-pocket cap marks the program’s biggest draw in 2026, encompassing deductibles, copays, and coinsurance – but excluding premiums. Certain assistance like Extra Help counts toward this limit. Medicare also introduced lower negotiated prices on 10 high-cost drugs, further easing burdens for specific conditions.[3][1]

Enrollment Shifts and Plan Selection Strategies

Part D reached 56.1 million enrollees by early 2026, with 44% in stand-alone plans and 56% bundled into Medicare Advantage options. Stand-alone enrollment rose by 1.7 million year-over-year, fueled by employer group growth, while Advantage drug plans saw a slight dip.[4] Beneficiaries faced fewer stand-alone choices – averaging 11 per person – compared to dozens in Advantage.

Annual open enrollment runs October 15 to December 7, with changes effective January 1. Tools on Medicare.gov help compare plans by checking formularies against personal prescriptions. Low-income qualifiers should explore Extra Help to slash premiums and cost-sharing.

As prescription prices continue to climb, Part D’s 2026 updates deliver tangible relief at the pharmacy counter. Beneficiaries who review their coverage now stand to maximize savings on essential retail drugs.